Literature DB >> 19347116

Testing intravitreal toxicity of rapamycin in rabbit eyes.

Roberta Pereira de Almeida Manzano1, Gholam A Peyman, Palwasha Khan, Muhamet Kivilcim, Patricia Chevez-Barrios, Walter Takahashi.   

Abstract

PURPOSE: To evaluate retinal toxicity of varying doses of rapamycin when injected intravitreally in rabbits. Rapamycin is a potent immunosuppressive agent with significant antitumor and antiangiogenic properties, clinically approved for prevention of organ transplant rejection.
METHODS: Twelve New Zealand albino rabbits were divided into four groups. Four different doses of rapamycin were prepared in 0.1 ml: 20 microg, 50 microg, 200 microg, and 1000 microg. Each concentration was injected in one eye of three rabbits, and 0.1 ml volume of sterile BSS was injected into the contralateral eye of the three rabbits. Slit-lamp and fundoscopic examinations were performed and the animals were observed for 2 weeks for signs of infection, inflammation, and toxicity. A baseline ERG was performed before drug treatment and at day 14, after which the rabbits were euthanized. Histology of the enucleated eyes was studied to look for retinal toxicity.
RESULTS: ERG results showed some decrease in scotopic response; however this was not dose related. ERG results were normal at 20 microg. Histological results showed no retinal toxicity in all groups.
CONCLUSION: Although ERG changes were identified at dosages between 50-1000 microg, the histology of all groups up to 1000 microg did not show any discernable abnormalities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19347116     DOI: 10.1590/s0004-27492009000100004

Source DB:  PubMed          Journal:  Arq Bras Oftalmol        ISSN: 0004-2749            Impact factor:   0.872


  6 in total

Review 1.  A comprehensive review of intravitreal immunosuppressants and biologicals used in ophthalmology.

Authors:  Nasiq Hasan; Rohan Chawla; Nawazish Shaikh; Sindhuja Kandasamy; Shorya Vardhan Azad; M Dheepak Sundar
Journal:  Ther Adv Ophthalmol       Date:  2022-05-18

2.  Toxicity and in vivo release profile of sirolimus from implants into the vitreous of rabbits' eyes.

Authors:  Mayara Rodrigues Brandão De Paiva; Nayara Almeida Lage; Maria Carolina Andrade Guerra; Marcos Paulo Gomes Mol; Marcela Coelho Silva Ribeiro; Gustavo De Oliveira Fulgêncio; Dawidson A Gomes; Isabela Da Costa César; Sílvia Ligório Fialho; Armando Silva-Cunha
Journal:  Doc Ophthalmol       Date:  2018-11-19       Impact factor: 2.379

3.  Pharmacokinetics, electrophysiological, and morphological effects of the intravitreal injection of mycophenolic acid in rabbits.

Authors:  Fabio Gasparin; Renata Genaro Aguiar; Gabriela Lourençon Ioshimoto; Armando Silva-Cunha; Silvia Ligório Fialho; André Mauricio Liber; Balázs Vince Nagy; Nestor Norio Oiwa; Marcelo Fernandes Costa; Christina Joselevitch; Dora Fix Ventura; Francisco Max Damico
Journal:  J Ocul Pharmacol Ther       Date:  2014-05-14       Impact factor: 2.671

4.  A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis.

Authors:  Brandon N Phillips; Keith J Wroblewski
Journal:  J Ophthalmic Inflamm Infect       Date:  2010-12-07

5.  In vivo and in vitro toxicity evaluation of liposome-encapsulated sirolimus.

Authors:  Murilo Batista Abud; Ricardo Noguera Louzada; David Leonardo Cruvinel Isaac; Leonardo Gomes Souza; Ricardo Gomes Dos Reis; Eliana Martins Lima; Marcos Pereira de Ávila
Journal:  Int J Retina Vitreous       Date:  2019-09-24

6.  mTORC1 Activation in Chx10-Specific Tsc1 Knockout Mice Accelerates Retina Aging and Degeneration.

Authors:  Yu-Qing Rao; Yu-Tong Zhou; Wenchuan Zhou; Jia-Kai Li; Baojie Li; Jing Li
Journal:  Oxid Med Cell Longev       Date:  2021-11-05       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.